Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | C1S | P09871 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1801548 | 0.88 | PLAU (0.46) | RXFP1PLK1MAPK14MAPTKDM4E | |
| SCHEMBL12441421 | 0.87 | ALOX5 (0.40) | ALOX5RXFP1PLK1MAPTPLAU | |
| SCHEMBL10088560 | 0.84 | OPRD1 (0.47) | ALOX5RXFP1MAPTKDM4ELMNA | |
| SCHEMBL1797134 | 0.80 | CLK1 (0.42) | ALOX5RXFP1HPGDSMN1; SMN2 | |
| SCHEMBL1797130 | 0.79 | RXFP1 (0.47) | ALOX5RXFP1PLK1MAPTKDM4E | |
| SCHEMBL1802291 | 0.76 | PLAU (0.47) | RXFP1PLK1KDM4ELMNAPLAU | |
| SCHEMBL10088521 | 0.76 | CYP2A6 (0.40) | ALOX5BACE1 | |
| SCHEMBL1802075 | 0.76 | S1PR1 (0.38) | ALOX5RXFP1MAPTHPGD | |
| SCHEMBL1801707 | 0.76 | PLK1 (0.43) | RXFP1PLK1MAPK14MAPTKDM4E | |
| SCHEMBL1801983 | 0.74 | MAPK14 (0.42) | MAPK14MAPTKDM4EPKMPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951794-B2 | Thiophene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-31 | — | — | US | disclosed |
| US-20100075946-A1 | NOVEL THIOPHENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-25 | — | — | US | disclosed |
| EP-1896446-A1 | NOVEL THIOPHENE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006137019-A1 | NOVEL THIOPHENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075946-A1 | NOVEL THIOPHENE DERIVATIVES | TPMT, TSLP, NFATC1 | ALOX5 1478/4885RXFP1 4565/4885PLK1 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.